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Clinical PerspectiveWhat Is New?In this longitudinal Taiwanese cohort study including 127 771 adults 65 years and older, serum uric acid (SUA) levels ≥8 or \<4 mg/dL were significantly associated with higher all‐cause and cardiovascular disease--related death as compared with the reference strata of 4 to \<5 mg/dL.Remarkably, low SUA (\<4 mg/dL)‐associated higher mortality risks were only significant in those with concomitant malnourishment, defined as either Geriatric Nutritional Risk Index \<98, serum albumin \<38 g/L, or body mass index \<22 kg/m^2^.What Are the Clinical Implications?SUA levels of 4 to \<8 mg/dL are associated with lowest all‐cause and cardiovascular disease--related mortality in the elderly Taiwanese population.Older people with malnourishment have significantly heightened low SUA‐associated mortality than those without.A low SUA level (\<4 mg/dL) is an overlooked prognostic factor that can help risk‐stratify older people.

 {#jah32966-sec-0008}

Older people are currently the fastest‐growing segment of the population, and the number of elderly people is expected to increase from 841 million in 2013 to more than 2 billion in 2050.[1](#jah32966-bib-0001){ref-type="ref"} Cardiovascular disease (CVD) is the leading cause of death in the older population, and the prevalence and incidence of CVD increases exponentially with advancing age.[2](#jah32966-bib-0002){ref-type="ref"} Uric acid, the final product of purine degradation in humans, mediates proinflammatory endothelial dysfunction and is associated with greater risks for CVD events.[3](#jah32966-bib-0003){ref-type="ref"}, [4](#jah32966-bib-0004){ref-type="ref"} Although a wealth of research has reported that an elevated serum uric acid (SUA) level \>7 mg/dL independently predicts all‐cause and CVD‐related mortality in middle‐aged adults,[5](#jah32966-bib-0005){ref-type="ref"}, [6](#jah32966-bib-0006){ref-type="ref"}, [7](#jah32966-bib-0007){ref-type="ref"} studies linking hyperuricemia to mortality risks in the elderly population are conflicting and inconclusive.[8](#jah32966-bib-0008){ref-type="ref"}, [9](#jah32966-bib-0009){ref-type="ref"}, [10](#jah32966-bib-0010){ref-type="ref"}, [11](#jah32966-bib-0011){ref-type="ref"}, [12](#jah32966-bib-0012){ref-type="ref"}, [13](#jah32966-bib-0013){ref-type="ref"}, [14](#jah32966-bib-0014){ref-type="ref"} Earlier studies indicate that hyperuricemia is associated with increased risks of death from any causes and CVD‐related mortality in older adults.[8](#jah32966-bib-0008){ref-type="ref"}, [9](#jah32966-bib-0009){ref-type="ref"}, [10](#jah32966-bib-0010){ref-type="ref"}, [11](#jah32966-bib-0011){ref-type="ref"} Nonetheless, several recent studies fail to identify such an association between high SUA levels and increased mortality risks in the aging population.[12](#jah32966-bib-0012){ref-type="ref"}, [13](#jah32966-bib-0013){ref-type="ref"}, [14](#jah32966-bib-0014){ref-type="ref"} These contradictory results may be attributed to the differences in cohort characteristics, adjustment of confounders, and sample size. In addition, the reference SUA levels among these studies are uneven[8](#jah32966-bib-0008){ref-type="ref"}, [9](#jah32966-bib-0009){ref-type="ref"}, [10](#jah32966-bib-0010){ref-type="ref"}, [11](#jah32966-bib-0011){ref-type="ref"}, [12](#jah32966-bib-0012){ref-type="ref"}, [13](#jah32966-bib-0013){ref-type="ref"}, [14](#jah32966-bib-0014){ref-type="ref"} and most studies categorize participants by quantiles,[8](#jah32966-bib-0008){ref-type="ref"}, [9](#jah32966-bib-0009){ref-type="ref"}, [10](#jah32966-bib-0010){ref-type="ref"}, [12](#jah32966-bib-0012){ref-type="ref"}, [13](#jah32966-bib-0013){ref-type="ref"}, [14](#jah32966-bib-0014){ref-type="ref"} which markedly hamper the comparability and clinical applicability of these studies.

Apart from hyperuricemia, low SUA concentrations have recently been suggested to correlate with higher coronary mortality in elderly people with diabetes mellitus as well.[8](#jah32966-bib-0008){ref-type="ref"} This inverse association between low SUA levels and mortality, although the underlying pathophysiologic mechanism is unclear, has also been documented in patients with untreated hypertension[15](#jah32966-bib-0015){ref-type="ref"} or end‐stage renal disease.[16](#jah32966-bib-0016){ref-type="ref"} A better understanding of the reasons behind such a paradoxical association is pivotal to help determine target SUA levels for elderly people and other patient groups different from the general population.[15](#jah32966-bib-0015){ref-type="ref"}, [16](#jah32966-bib-0016){ref-type="ref"} Older adults have age‐related change of appetite regulation and are predisposed to decreased food intake and malnourishment.[17](#jah32966-bib-0017){ref-type="ref"}, [18](#jah32966-bib-0018){ref-type="ref"} Malnourishment is an independent risk factor for all‐cause and CVD‐related mortality in older people.[19](#jah32966-bib-0019){ref-type="ref"} Moreover, dietary fat and meat intake are positively correlated with SUA levels in the elderly[20](#jah32966-bib-0020){ref-type="ref"} and malnourishment also contributes to low SUA levels. Hence, we hypothesized that malnourishment may affect low SUA‐associated mortality in older adults.

Currently, there is no consensus regarding the optimal range of SUA levels among elderly people.[21](#jah32966-bib-0021){ref-type="ref"} Furthermore, little is known about how low SUA levels link to heightened mortality risks. Therefore, the present study aimed to investigate the SUA levels with lowest all‐cause and cardiovascular mortality in a large population‐based elderly cohort. Furthermore, we delineated the role of malnourishment in modifying the association of low SUA levels and increased mortality.

Methods {#jah32966-sec-0009}
=======

Data Source {#jah32966-sec-0010}
-----------

The data and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure because access to these data is contractually controlled by the Taipei City Hospital and the Department of Health, Taipei City Government. Only analytic methods are available on request. A request for the analytic methods should be sent to the corresponding author.

Our study was based on a large, well‐characterized cohort of older people in Taipei City, Taiwan.[22](#jah32966-bib-0022){ref-type="ref"}, [23](#jah32966-bib-0023){ref-type="ref"} Since 2001, the Taipei City Government has launched an annual, free‐of‐charge, comprehensive health examination program for all citizens 65 years and older to promote the health of senior citizens.[24](#jah32966-bib-0024){ref-type="ref"} Detailed information regarding height, weight, blood pressure (BP), and medical history were recorded at the examinations. Demographic and lifestyle data including marital status, education level, smoking history, alcohol consumption, and exercise habits were collected through a self‐administered questionnaire. Overnight fasting blood samples were collected at the first visit for the measurement of complete blood cell count, serum blood sugar, triglyceride, total cholesterol, high‐density‐lipoprotein cholesterol, albumin, blood urea nitrogen, creatinine, and uric acid. The SUA levels were assayed by the colorimetric uricase--peroxidase system.[25](#jah32966-bib-0025){ref-type="ref"} All participants provided written informed consent authorizing the Taipei City Government to process the health examination data for research purposes. Detailed deidentified data were stored centrally in the Taipei City Elderly Health Examination Database, which was linked to the Taiwan National Death Registry System. The acquisition and processing of the data for the present study was approved by the institutional review board of the Taipei City Hospital (TCHIRB‐1010323‐E and TCHIRB‐1030601‐W).

Definition of Malnourishment and Study Design {#jah32966-sec-0011}
---------------------------------------------

A simple and well‐established tool, the Geriatric Nutritional Risk Index (GNRI),[26](#jah32966-bib-0026){ref-type="ref"}, [27](#jah32966-bib-0027){ref-type="ref"} was used to assess the nutritional risk of each participant and calculated as follows: GNRI=\[1.489×albumin (g/L)\]+\[41.7×(actual weight/ideal weight)\].[26](#jah32966-bib-0026){ref-type="ref"} The ideal weight was calculated by the Lorentz formula.[26](#jah32966-bib-0026){ref-type="ref"} Furthermore, a body mass index (BMI) of 22 kg/m^2^ is associated with the lowest morbidity in Asians.[28](#jah32966-bib-0028){ref-type="ref"} Therefore, participants with adequate nutritional status were defined as having a GNRI ≥98,[26](#jah32966-bib-0026){ref-type="ref"} a serum albumin level ≥38 g/L,[26](#jah32966-bib-0026){ref-type="ref"} and a BMI ≥22 kg/m^2^.[28](#jah32966-bib-0028){ref-type="ref"} Participants with malnourishment were further categorized into mildly or severely malnourished groups. The mildly malnourished groups were defined as those having either a GNRI ≥82 but \<98, a serum albumin level ≥30 but \<38 g/L, or a BMI ≥19 but \<22 kg/m^2^. The severely malnourished groups were defined as those having either a GNRI \<82, a serum albumin level \<30 g/L, or a BMI \<19 kg/m^2^.[26](#jah32966-bib-0026){ref-type="ref"} Estimated glomerular filtration rate (eGFR) was calculated by the Chronic Kidney Disease Epidemiology Collaboration equation.[29](#jah32966-bib-0029){ref-type="ref"}

From 2001 to 2010, 132 988 participants 65 years and older were initially screened. Participants lacking SUA levels (n=51) or GNRI (n=3363) data, or having a history of end‐stage renal disease (n=1629), were excluded. Those (n=186) with extremely low SUA levels (\<2 mg/dL) that were possibly ascribed to hereditary renal hypouricemia were also excluded.[30](#jah32966-bib-0030){ref-type="ref"} Ultimately, 127 771 participants were enrolled in the study (Figure [S1](#jah32966-sup-0001){ref-type="supplementary-material"}).

Study Outcome and Follow‐up {#jah32966-sec-0012}
---------------------------

The mortality data were obtained from the National Death Registry System and coded from death certificates according to the *International Classification of Diseases, Ninth Revision (ICD‐9)* or *Tenth Revision (ICD‐10)*. The study outcomes were all‐cause mortality (*ICD‐9* 001.x--999.x or *ICD‐10* A00.x--Z99.x) and CVD‐related death (*ICD‐9* 393.x--459.x; *ICD‐10* I07.x--I77.x, I99.x, J00.x, and J04.x). The accuracy of cause‐of‐death codes in Taiwan\'s National Death Registry database has been validated.[31](#jah32966-bib-0031){ref-type="ref"} All participants were followed until death or December 31, 2010, whichever occurred first.

Statistical Analysis {#jah32966-sec-0013}
--------------------

To detect nonlinear associations and better delineate the effects of low and high SUA levels on mortality, the study participants were stratified by 1‐mg/dL increment of SUA level and categorized into 9 a priori--defined groups as 2 to \<3, 3 to \<4, 4 to \<5, 5 to \<6, 6 to \<7, 7 to \<8, 8 to \<9, 9 to \<10, and ≥10 mg/dL. Participants with SUA levels of 4 to \<5 mg/dL were set as the reference group based on a previous study showing that CVD and mortality risks increase once the SUA levels exceed 5.0 mg/dL in middle‐aged adults.[6](#jah32966-bib-0006){ref-type="ref"} Data were described as percentages for categorical variables and means±standard deviations for continuous variables. Baseline characteristics were compared by Student *t* test, 1‐way ANOVA, or χ^2^ test, where appropriate. Kaplan--Meier plots were generated to estimate the cumulative incidence of all‐cause and CVD mortality among older people with or without malnourishment, and the difference between the curves was compared by log‐rank test. Cox proportional hazards models were applied to estimate the hazard ratios of study outcomes after adjusting for age, sex, BMI, smoking, alcohol consumption, systolic BP, diastolic BP, history of hypertension, diabetes mellitus, dyslipidemia, coronary artery disease, cerebrovascular disease, baseline eGFR, serum total cholesterol, triglyceride, high‐density lipoprotein cholesterol, hemoglobin, fasting glucose, white blood cell count, and albumin levels. To further examine the continuous association between SUA levels and mortality, we fit restricted cubic spline models for SUA, and the SUA level of 4.5 mg/dL was used as the reference point. A *P* value for nonlinearity was calculated using a null hypothesis test. The likelihood ratio test was used to examine the interaction between SUA levels and the following variables: malnourishment status, sex, age, baseline eGFR, smoking, history of diabetes mellitus, hypertension, and coronary artery disease. Subgroup analyses were also performed accordingly. Glycated hemoglobin has been shown to interact with SUA levels in Japanese community‐dwelling older adults.[32](#jah32966-bib-0032){ref-type="ref"} Hence, the interaction between fasting blood glucose and SUA levels on mortality was also explored. All *P* values were 2‐sided, and the significance level was set at 0.05. Bonferroni correction was used to avoid the inflation of type I error caused by multiple testing where applicable. All analyses were conducted with STATA statistical software (Stata SE, version 13.0; StataCorp).

Results {#jah32966-sec-0014}
=======

Patient Characteristics {#jah32966-sec-0015}
-----------------------

A total of 127 771 eligible participants (66 632 men and 61 139 women) were identified in the data set from 2001 to 2010. Table [1](#jah32966-tbl-0001){ref-type="table-wrap"} shows the demographic characteristics of the cohort stratified by the SUA levels. The mean age of the cohort was 72.6±6.3 years. A total of 54.2% and 11.8% of the participants had hypertension or diabetes mellitus, respectively. Compared with the reference group (SUA levels: 4 to \<5 mg/dL), participants with higher SUA levels were older, mostly male, tended to be smokers, had higher BMIs and BP and fasting glucose levels, and higher prevalence rates of hypertension, diabetes mellitus, coronary artery disease, and cerebrovascular disease, but lower baseline eGFR. In contrast, the low SUA (\<4 mg/dL) group was also older and more likely to have coronary artery disease but had lower BMI, BP, and serum albumin levels and less dyslipidemia (Table [1](#jah32966-tbl-0001){ref-type="table-wrap"}).

###### 

Demographic and Clinical Characteristics of Study Population by SUA Level[a](#jah32966-note-0005){ref-type="fn"}

  Characteristics              All             SUA, mg/dL                                                                                                                           
  ---------------------------- --------------- ------------ ------------- --------------- --------------- --------------- --------------- ------------- ------------- ------------- ---------
  No. of participants          127 771         1472         7801          21 866          31 658          28 917          18 805          9969          4327          2956          
  Demographics                                                                                                                                                                      
  Male                         66 632 (52.1)   487 (33.1)   2192 (28.1)   7311 (33.4)     14 814 (46.8)   17 022 (58.9)   12 620 (67.1)   7001 (70.2)   3082 (71.2)   2103 (71.1)   \<0.001
  Age, y                       72.6±6.3        72.9±6.6     72.2±6.5      71.8±6.3        72.2±6.2        72.6±6.2        73.0±6.2        73.5±6.2      74.0±6.3      74.7±6.4      \<0.001
  Smoking                      12 952 (10.1)   101 (6.9)    467 (6.0)     1519 (6.9)      2887 (9.1)      3253 (11.2)     2446 (13.0)     1283 (12.9)   594 (13.7)    402 (13.6)    \<0.001
  Alcohol use                  19 129 (15.0)   138 (9.4)    657 (8.4)     2311 (10.6)     4428 (14.0)     4923 (17.0)     3605 (19.2)     1866 (18.7)   735 (17.0)    466 (15.8)    \<0.001
  BMI, kg/m^2^                 24.3±3.5        22.8±3.6     23.0±3.5      23.5±3.3        24.1±3.3        24.5±3.4        24.9±3.4        25.2±3.5      25.2±3.5      25.5±3.7      \<0.001
  Comorbidity                                                                                                                                                                       
  Hypertension                 69 220 (54.2)   783 (53.2)   3639 (46.6)   10 486 (48.0)   16 443 (51.9)   15 895 (55.0)   10 971 (58.3)   6178 (62.0)   2785 (64.4)   2040 (69.0)   \<0.001
  Diabetes mellitus            15 063 (11.8)   224 (15.2)   1052 (13.5)   2576 (11.8)     3654 (11.5)     3316 (11.5)     2155 (11.5)     1101 (11.0)   589 (13.6)    396 (13.4)    \<0.001
  Dyslipidemia                 66 681 (52.2)   737 (50.1)   4095 (52.5)   11 685 (53.4)   16 595 (52.4)   14 933 (51.6)   9558 (50.8)     5212 (52.3)   2321 (53.6)   1545 (52.3)   \<0.001
  Coronary artery disease      14 870 (11.6)   156 (10.6)   815 (10.4)    2242 (10.3)     3326 (10.5)     3310 (11.4)     2488 (13.2)     1422 (14.3)   640 (14.8)    471 (15.9)    \<0.001
  Cerebrovascular disease      1094 (0.9)      13 (0.9)     79 (1.0)      150 (0.7)       278 (0.9)       238 (0.8)       168 (0.9)       94 (0.9)      50 (1.2)      24 (0.8)      0.012
  Blood pressure, mm Hg                                                                                                                                                             
  Systolic                     135.7±20.1      133.5±20.1   133.3±20.4    134.3±20.1      135.1±20.0      136.1±19.9      136.9±19.9      137.8±19.7    138.3±20.6    139.1±21.0    \<0.001
  Diastolic                    77.1±11.9       76.4±12.3    75.8±11.8     76.1±11.6       76.8±11.6       77.3±11.8       77.8±12.0       78.4±12.2     78.4±12.8     78.3±13.0     \<0.001
  eGFR, mL/min per 1.73 m^2^                                                                                                                                                        \<0.001
  ≥90                          13 003 (10.2)   288 (19.6)   1718 (22.0)   4110 (18.8)     3819 (12.1)     2062 (7.1)      679 (3.6)       218 (2.2)     75 (1.7)      34 (1.2)      
  60 to 89                     71 039 (55.6)   871 (59.2)   4563 (58.5)   13 376 (61.2)   19 580 (61.8)   16 842 (58.2)   9605 (51.1)     4121 (41.3)   1402 (32.4)   679 (23.0)    
  45 to 59                     31 639 (24.8)   248 (16.8)   1250 (16.0)   3620 (16.6)     6593 (20.8)     7643 (26.4)     6052 (32.2)     3667 (36.8)   1536 (35.5)   1030 (34.8)   
  30 to 44                     9363 (7.3)      48 (3.3)     211 (2.7)     622 (2.8)       1364 (4.3)      1885 (6.5)      1926 (10.2)     1517 (15.2)   979 (22.6)    811 (27.4)    
  15 to 29                     2075 (1.6)      13 (0.9)     30 (0.4)      76 (0.3)        196 (0.6)       349 (1.2)       432 (2.3)       364 (3.7)     287 (6.6)     328 (11.1)    
  \<15                         652 (0.5)       4 (0.3)      29 (0.4)      62 (0.3)        106 (0.3)       136 (0.5)       111 (0.6)       82 (0.8)      48 (1.1)      74 (2.5)      
  Total cholesterol, mmol/L    5.18±0.97       5.13±1.02    5.19±0.96     5.22±0.96       5.19±0.96       5.17±0.96       5.15±0.98       5.17±1.02     5.2±1.06      5.18±1.09     \<0.001
  Triglycerides, mmol/L        1.47±0.60       1.37±0.47    1.37±0.60     1.40±0.53       1.44±0.57       1.49±0.55       1.52±0.59       1.55±0.81     1.58±0.74     1.60±0.95     \<0.001
  HDL cholesterol, mmol/L      1.39±0.23       1.44±0.04    1.46±0.05     1.43±0.02       1.39±0.24       1.36±0.21       1.35±0.19       1.35±0.18     1.34±0.17     1.35±0.19     \<0.001
  WBC count, cells×10^9^/L     6.10±1.83       5.85±1.82    5.74±1.75     5.84±1.89       5.98±1.67       6.13±1.79       6.31±1.86       6.46±1.95     6.6±1.99      6.79±2.15     \<0.001
  Albumin, g/L                 43±3            42±4         43±3          43±3            43±3            43±3            43±3            43±3          43±3          43±4          \<0.001
  Hemoglobin, g/L              135±14          131±14       131±13        133±13          135±14          137±14          138±15          138±16        136±17        134±18        \<0.001
  Fasting glucose, mmol/L      5.96±1.73       6.14±2.37    5.99±2.02     5.93±1.83       5.92±1.68       5.94±1.63       5.97±1.61       5.99±1.51     6.13±2.08     6.14±1.86     \<0.001

BMI indicates body mass index; eGFR, estimated glomerular filtration rate; HDL, high‐density lipoprotein; SUA, serum uric acid; WBC, white blood cell.

Values for categorical and continuous variables are given as numbers (percentages) and as means±standard deviation, respectively.

U‐shaped Association Between SUA and Outcomes {#jah32966-sec-0016}
---------------------------------------------

Over a median follow‐up of 5.8 years, 16 439 patients died from any causes and 3877 patients experienced CVD‐related death. As compared with the reference group, both higher and lower SUA strata had elevated risks toward all‐cause and CVD mortality (Figure [1](#jah32966-fig-0001){ref-type="fig"}, model 1; Table [S1](#jah32966-sup-0001){ref-type="supplementary-material"}). There was a progressively higher risk for all‐cause mortality when the SUA level exceeded 8 mg/dL, and there was also an incrementally higher risk for CVD mortality once the SUA level surpassed 7 mg/dL. Notably, the risks for all‐cause and CVD mortalities also increased when the SUA level was \<4 mg/dL. This U‐shaped association between SUA levels with all‐cause and CVD mortality remained consistent after adjusting for demographic, comorbidity, and biochemical laboratory parameters (Figure [1](#jah32966-fig-0001){ref-type="fig"}, model 2--4; Table [S1](#jah32966-sup-0001){ref-type="supplementary-material"}). The *P* value for test of linearity hypotheses was \<0.001, confirming the nonlinear relationship between SUA levels and mortality risk. Although the SUA ≥10 mg/dL group had the highest risk for all‐cause and CVD mortality, the risks for all‐cause and CVD mortality in the 2 to \<3 mg/dL SUA stratum were 20% and 35% higher than the reference group, comparable to those in the 9 to \<10 mg/dL SUA stratum. The association between SUA levels with all‐cause (*P* for interaction=0.254) and CVD (*P* for interaction=0.467) mortality was not affected by fasting glucose levels (≥8 mmol/L or \<8 mmol/L).

![U‐shaped association between serum uric acid level with (A) all‐cause and (B) cardiovascular disease (CVD) mortality among 127 771 older people. Hazard ratios (HRs) (95% confidence intervals) of serum uric acid categories associated with (A) all‐cause and (B) CVD mortality in Cox models are depicted. Model 1 was an unadjusted crude HR. Model 2 was adjusted for age and sex. Model 3 was adjusted for age, sex, smoking, alcohol consumption, body mass index, systolic blood pressure, and baseline comorbidities (hypertension, diabetes mellitus, dyslipidemia, coronary artery disease, and cerebrovascular disease). Model 4 included covariates from model 3, as well as laboratory biochemical profiles. Serum uric acid category of 4 to \<5 mg/dL served as reference.](JAH3-7-e007523-g001){#jah32966-fig-0001}

Malnourishment Status and Low SUA‐Associated Increased Mortality {#jah32966-sec-0017}
----------------------------------------------------------------

To investigate the role of nutritional status in low SUA‐associated worse outcomes, participants were further stratified by malnourishment status. Participants with malnourishment were predominantly women and older and had a higher percentage of smoking and cerebrovascular disease; a lower percentage of hypertension, diabetes mellitus, dyslipidemia, and coronary artery disease; and lower eGFR and BMI levels (Table [S2](#jah32966-sup-0001){ref-type="supplementary-material"}). Kaplan--Meier curves showed that participants with malnourishment were associated with a higher chance for all‐cause and CVD mortalities as compared with adequately nourished people (Figure [S2](#jah32966-sup-0001){ref-type="supplementary-material"}), and the risks remained significant after adjusting for other demographic characteristics and potential confounders (Table [S3](#jah32966-sup-0001){ref-type="supplementary-material"}). Tests of interaction were significant for malnourishment and SUA levels (*P*=0.013 for all‐cause mortality and *P*=0.006 for CVD mortality, Table [2](#jah32966-tbl-0002){ref-type="table-wrap"}). The U‐shaped association between SUA levels with all‐cause mortality was still present in participants with malnourishment when Bonferroni correction was applied for multiple testing (ie, using a significance level of *P*=0.0083 \[0.05/6\]). Remarkably, in those without malnourishment, the mortality risk difference between the low SUA group and the reference group did not reach statistical significance (Figure [2](#jah32966-fig-0002){ref-type="fig"}, Table [2](#jah32966-tbl-0002){ref-type="table-wrap"}), indicating an effect‐modifying role of malnourishment. Furthermore, the mortality risks associated with low SUA levels were progressively higher when the severity of malnourishment advanced (Figure [3](#jah32966-fig-0003){ref-type="fig"}, Table [S4](#jah32966-sup-0001){ref-type="supplementary-material"}).

###### 

Association Between SUA Level and Risks of Mortality in Older People by Malnourishment Status

  SUA, mg/dL                 Total Participants   Malnourishment Status[a](#jah32966-note-0007){ref-type="fn"}                                                                               
  -------------------------- -------------------- -------------------------------------------------------------- --------- -------- ------------------- --------- ------ ------------------- ---------
  All‐cause mortality                                                                                                                                                                        
  2 to \<3                   1472                 1.19 (1.03--1.37)                                              0.019     782      0.95 (0.74--1.22)   0.691     690    1.26 (1.05--1.50)   0.012
  3 to \<4                   7801                 1.16 (1.07--1.25)                                              \<0.001   4344     1.09 (0.97--1.23)   0.135     3457   1.18 (1.06--1.31)   0.002
  4 to \<5                   21 866               Reference                                                                13 508   Reference                     8358   Reference           
  5 to \<6                   31 658               0.96 (0.91--1.01)                                              0.148     22 018   0.96 (0.89--1.03)   0.278     9640   0.99 (0.92--1.07)   0.770
  6 to \<7                   28 917               0.99 (0.93--1.04)                                              0.590     21 594   0.97 (0.90--1.04)   0.383     7323   1.03 (0.96--1.12)   0.401
  7 to \<8                   18 805               1.05 (0.99--1.11)                                              0.139     14 608   1.02 (0.94--1.10)   0.620     4197   1.09 (1.00--1.19)   0.063
  8 to \<9                   9969                 1.13 (1.06--1.21)                                              \<0.001   7853     1.08 (0.99--1.18)   0.073     2116   1.19 (1.07--1.32)   0.001
  9 to \<10                  4327                 1.20 (1.10--1.30)                                              \<0.001   3403     1.14 (1.02--1.26)   0.019     924    1.28 (1.12--1.47)   \<0.001
  ≥10                        2956                 1.51 (1.39--1.65)                                              \<0.001   2299     1.42 (1.27--1.58)   \<0.001   657    1.60 (1.39--1.83)   \<0.001
  Cardiovascular mortality                                                                                                                                                                   
  2 to \<3                   1472                 1.36 (1.02--1.82)                                              0.039     782      0.97 (0.58--1.61)   0.900     690    1.57 (1.09--2.25)   0.015
  3 to \<4                   7801                 1.19 (1.00--1.40)                                              0.047     4344     1.00 (0.78--1.29)   0.995     3457   1.33 (1.06--1.66)   0.015
  4 to \<5                   21 866               Reference                                                                13 508   Reference                     8358   Reference           
  5 to \<6                   31 658               0.98 (0.87--1.10)                                              0.738     22 018   0.90 (0.77--1.06)   0.212     9640   1.10 (0.93--1.30)   0.275
  6 to \<7                   28 917               1.03 (0.92--1.15)                                              0.644     21 594   0.90 (0.77--1.06)   0.212     7323   1.23 (1.04--1.46)   0.015
  7 to \<8                   18 805               1.17 (1.04--1.32)                                              0.011     14 608   1.12 (0.96--1.32)   0.138     4197   1.19 (0.98--1.44)   0.079
  8 to \<9                   9969                 1.24 (1.08--1.42)                                              0.002     7853     1.12 (0.93--1.33)   0.218     2116   1.42 (1.14--1.76)   0.002
  9 to \<10                  4327                 1.35 (1.14--1.59)                                              \<0.001   3403     1.20 (0.97--1.47)   0.096     924    1.59 (1.21--2.08)   0.001
  ≥10                        2956                 1.67 (1.41--1.99)                                              \<0.001   2299     1.61 (1.30--1.98)   \<0.001   657    1.55 (1.14--2.10)   0.005

CI indicates confidence interval; HR, hazard ratio; SUA, serum uric acid.

*P* ~Interaction~=0.013 for all‐cause mortality, and *P* ~Interaction~=0.006 for cardiovascular mortality.

Adjusted for age, sex, body mass index, smoking, alcohol drinking, comorbidities, and all biochemical data in Table [1](#jah32966-tbl-0001){ref-type="table-wrap"}.

![Cubic spline models for the association between serum uric acid (SUA) levels with (A through C) all‐cause and (D through F) cardiovascular disease (CVD) mortality among 127 771 older people, stratified by malnourishment status. Hazard ratios (HRs) were adjusted for age, sex, body mass index, smoking, alcohol consumption, blood pressure, estimated glomerular filtration rate, hypertension, diabetes mellitus, dyslipidemia, coronary artery disease, cerebrovascular disease, serum total cholesterol, triglycerides, high‐density lipoprotein cholesterol, hemoglobin, fasting glucose, white blood cell count, and albumin. Filled circles denote statistical significance (*P*\<0.05) compared with the reference (diamond) SUA level of 4.5 mg/dL. Solid line (---) denotes adjusted HR and dash line (‐ ‐ ‐) denotes 95% confidence intervals (CIs).](JAH3-7-e007523-g002){#jah32966-fig-0002}

![Risks of (A) all‐cause and (B) cardiovascular disease (CVD) mortality by malnourishment status among participants with low serum uric acid (\<4 mg/dL). Participants with a serum uric acid level of 4 to \<5 mg/dL served as the reference group.](JAH3-7-e007523-g003){#jah32966-fig-0003}

Subgroup Analyses {#jah32966-sec-0018}
-----------------

The effect‐modifying role of malnourishment in low SUA‐associated higher mortality was examined in different subgroups of sex, age, eGFR, smoking status, diabetes mellitus, hypertension, and coronary artery disease. The inverse associations between low SUA levels with all‐cause and CVD mortalities were consistent across all subgroups of the malnourished participants (Figure [4](#jah32966-fig-0004){ref-type="fig"}).

![Subgroup analyses for effect modification by malnourishment status on (A) all‐cause and (B) cardiovascular disease (CVD) mortality risks in participants with low serum uric acid (SUA, \<4 mg/dL) as compared to those with SUA of 4 to \<5 mg/dL. The risks were presented as hazard ratios (HRs) and 95% confidence intervals (CIs) after adjusting for all variables in Table [1](#jah32966-tbl-0001){ref-type="table-wrap"}. eGFR indicates estimated glomerular filtration rate.](JAH3-7-e007523-g004){#jah32966-fig-0004}

Discussion {#jah32966-sec-0019}
==========

By utilizing a large population‐based cohort, the present study found that heightened risks for all‐cause and CVD mortality were not only observed in people older than 65 years with SUA levels ≥8 mg/dL but also in those with SUA levels \<4 mg/dL, forming a U‐shaped association for mortality and SUA levels. To the best of our knowledge, this is the largest study to investigate the association between SUA and mortality in the elderly. Previous studies have suggested that hyperuricemia at the top quantile[8](#jah32966-bib-0008){ref-type="ref"}, [9](#jah32966-bib-0009){ref-type="ref"}, [10](#jah32966-bib-0010){ref-type="ref"} or \>7.0 mg/dL[11](#jah32966-bib-0011){ref-type="ref"} is associated with a higher risk for CVD‐related mortality. Conversely, other investigations failed to demonstrate the independent predictive role of hyperuricemia for CVD‐related or all‐cause mortality in adults 65 years and older.[12](#jah32966-bib-0012){ref-type="ref"}, [13](#jah32966-bib-0013){ref-type="ref"}, [14](#jah32966-bib-0014){ref-type="ref"} Limitations pertaining to small sample size,[8](#jah32966-bib-0008){ref-type="ref"}, [10](#jah32966-bib-0010){ref-type="ref"}, [11](#jah32966-bib-0011){ref-type="ref"}, [12](#jah32966-bib-0012){ref-type="ref"}, [13](#jah32966-bib-0013){ref-type="ref"}, [14](#jah32966-bib-0014){ref-type="ref"} specific patient groups,[8](#jah32966-bib-0008){ref-type="ref"}, [11](#jah32966-bib-0011){ref-type="ref"}, [13](#jah32966-bib-0013){ref-type="ref"}, [14](#jah32966-bib-0014){ref-type="ref"} single sex,[9](#jah32966-bib-0009){ref-type="ref"} and incomplete adjustment for confounders such as eGFR,[9](#jah32966-bib-0009){ref-type="ref"}, [10](#jah32966-bib-0010){ref-type="ref"} fasting plasma glucose[10](#jah32966-bib-0010){ref-type="ref"}, [11](#jah32966-bib-0011){ref-type="ref"}, [12](#jah32966-bib-0012){ref-type="ref"} or alcohol consumption[9](#jah32966-bib-0009){ref-type="ref"}, [11](#jah32966-bib-0011){ref-type="ref"} jointly contribute to the conflicting results in these studies. Furthermore, all‐cause mortality, the ultimate clinical outcome measure of health, has not been investigated in certain studies.[8](#jah32966-bib-0008){ref-type="ref"}, [9](#jah32966-bib-0009){ref-type="ref"}, [11](#jah32966-bib-0011){ref-type="ref"} By extensively adjusting for potential confounders and stratifying participants by 1‐mg/dL increment in SUA, our large cohort study confirmed that hyperuricemia independently predicted mortality across all subgroups of older people. Moreover, we also determined that a threshold of ≥8 mg/dL was associated with increased risks for all‐cause and CVD‐related mortality.

Our study further found that an SUA level \<4 mg/dL was associated with greater mortality risks in the elderly population. Mazza et al[8](#jah32966-bib-0008){ref-type="ref"} analyzed 581 older patients with diabetes mellitus and suggested that SUA levels \<5 and ≥8 mg/dL were both associated with higher risks for coronary mortality as compared with SUA levels of 5 to \<6 mg/dL,[8](#jah32966-bib-0008){ref-type="ref"} raising the question of whether "lower is better" regarding SUA levels. Nonetheless, Strasak et al[9](#jah32966-bib-0009){ref-type="ref"} failed to demonstrate such a U‐shaped relation of SUA to mortality in elderly women. Small study cohort, single sex, and different patient groups in these studies preclude drawing a definite conclusion.[8](#jah32966-bib-0008){ref-type="ref"}, [9](#jah32966-bib-0009){ref-type="ref"} Meanwhile, Mazza et al[8](#jah32966-bib-0008){ref-type="ref"} did not distinguish the mortality risks between different SUA strata among participants with an SUA level \<5 mg/dL. We found that an SUA level \<4 mg/dL also carried higher risks for all‐cause and CVD‐related death, and the risks of mortality increased in a graded fashion according to decreasing SUA levels. Taken together, our large population‐based study was able to affirm the association between both extremes of SUA with increased all‐cause and CVD mortality. Our findings, on one hand, corroborated the link between high SUA levels with increased mortality. On the other hand, we highlighted the notion that a low SUA level was potentially harmful among older people. Our data provide important prognostic information to both physicians and patients, namely that an SUA level of 4 to \<8 mg/dL was associated with the lowest all‐cause and CVD‐related mortality rates in adults 65 years and older.

The most striking finding in the present study was that the association of a low SUA level with increased risk of all‐cause and CVD mortality is modified by nutritional status. In accordance with our findings, the inverse correlation between low SUA levels and mortality have also been reported in patients with untreated hypertension[15](#jah32966-bib-0015){ref-type="ref"} or end‐stage renal disease[16](#jah32966-bib-0016){ref-type="ref"} with unclear mechanisms. We found that a low SUA level was only predictive of increased mortality in older people who were malnourished, and this effect was nullified in those with adequate nutrition. Moreover, low SUA‐associated higher mortality was in parallel with the severity of malnourishment and consistent across all subgroups. Several potential mechanisms may explain the effect modification of malnourishment on low SUA‐associated mortality. First, a low SUA level has been proposed as a surrogate of inadequate protein and calorie intake in patients undergoing hemodialysis[33](#jah32966-bib-0033){ref-type="ref"} because SUA levels correlate with consumption of purine‐rich meat, seafood, and fat.[20](#jah32966-bib-0020){ref-type="ref"}, [34](#jah32966-bib-0034){ref-type="ref"} A recent report also found that frail malnourished older people who consumed less saturated fat and meat had lower SUA levels as compared with the community‐dwelling healthy elderly.[35](#jah32966-bib-0035){ref-type="ref"} It is plausible that protein‐energy wasting resulted in both low SUA levels and higher mortality in our malnourished participants. Second, low SUA levels in malnourished older people may parallel with vitamin C and D deficiency.[36](#jah32966-bib-0036){ref-type="ref"}, [37](#jah32966-bib-0037){ref-type="ref"} Deficiencies of these antioxidant and anti‐inflammatory vitamins have been linked to increased mortality.[38](#jah32966-bib-0038){ref-type="ref"}, [39](#jah32966-bib-0039){ref-type="ref"} Finally, low SUA levels may represent reduced total antioxidant capacity. Uric acid acts as a potent antioxidant and contributes to more than 50% of human plasma antioxidant capacity.[40](#jah32966-bib-0040){ref-type="ref"} Therefore, SUA might have predominantly acted as an antioxidant in our malnourished participants with SUA levels \<4 mg/dL and a relatively low BMI (Table [1](#jah32966-tbl-0001){ref-type="table-wrap"}). Given the decreased antioxidant capacity and malnourishment in our participants, a low SUA level may serve as a second hit that increases cardiovascular inflammation.[41](#jah32966-bib-0041){ref-type="ref"} Taken together, we found that malnourishment acted as an outcome modifier of the relationship between low SUA levels and mortality in the elderly, which help risk stratify older adults with low SUA levels and other distinct patient groups with low SUA‐associated mortality.[15](#jah32966-bib-0015){ref-type="ref"}, [16](#jah32966-bib-0016){ref-type="ref"}

Study Strengths {#jah32966-sec-0020}
---------------

The present study had several strengths. This is the first large‐scale cohort study to examine the association of SUA level with all‐cause and CVD mortality in older people. Utilization of a 127 771‐patient elderly cohort during a 10‐year study period provided adequate statistical power for the analysis of long‐term mortality outcomes. Second, by using 1‐mg/dL increments to stratify patients according to SUA level rather than using quantiles, our findings were more applicable to clinical decision‐making. Third, our study demonstrated that malnourishment was a critical determinant in modifying the low SUA‐associated mortality. Moreover, GNRI, the nutritional screening tool in our study, was clinically more useful because it is well‐validated, less time‐consuming, and did not require skilled personnel.[42](#jah32966-bib-0042){ref-type="ref"} Furthermore, GNRI has a higher prognostic value for classification of nutrition‐related complication in elderly patients than the Mini‐Nutritional Assessment test.[27](#jah32966-bib-0027){ref-type="ref"} It should be noted that the ideal BMI in this study was 22 kg/m^2^, which was more appropriate for Asian populations.[28](#jah32966-bib-0028){ref-type="ref"} Fourth, the causes of death were accurately identified from the Taiwan National Death Registry System[31](#jah32966-bib-0031){ref-type="ref"} and the survival status of all participants can be tracked. CVD mortality in our study accounted for 23.6% of all deaths, which is similar to the proportion (21.5%) of CVD mortality in the national statistics of cause of death.[43](#jah32966-bib-0043){ref-type="ref"}

Study Limitations {#jah32966-sec-0021}
-----------------

Several potential limitations should be acknowledged. A single baseline SUA level was used to predict mortality. Our study did not aim to assess the relationship between the change of SUA and mortality risks. A single measurement of SUA to predict outcomes was a simplified and practical approach, similar to what was done by previous researchers.[5](#jah32966-bib-0005){ref-type="ref"}, [6](#jah32966-bib-0006){ref-type="ref"}, [7](#jah32966-bib-0007){ref-type="ref"}, [8](#jah32966-bib-0008){ref-type="ref"}, [10](#jah32966-bib-0010){ref-type="ref"}, [11](#jah32966-bib-0011){ref-type="ref"} Information on diuretics and urate‐lowering agents was lacking in our study. The first National Health and Nutrition Examination Survey indicates that the association between SUA and mortality is independent of diuretic use,[5](#jah32966-bib-0005){ref-type="ref"} and we believed that diuretic use may not affect our results. Dietary intake assessment such as food record, 24‐hour dietary recall, or food frequency questionnaire was not implemented in our study. Whether the type and amount of food consumed affected SUA‐associated mortality was unclear. Furthermore, our population‐based elderly cohort did not include hospitalized or institutionalized older people. Finally, all study participants were Taiwanese and the conclusions may not be generalized to other ethnicities.

Conclusions {#jah32966-sec-0022}
===========

Our population‐based cohort study provided the epidemiologic evidence that elderly people have a U‐shaped association between SUA levels with all‐cause and CVD mortality. Either SUA levels ≥8 or \<4 mg/dL predicted higher mortality risks in the Taiwanese elderly. Malnourishment status significantly modified low SUA‐associated higher mortality. Clinicians should not ignore that malnourishment is a main factor causing an increased risk for mortality in older people with low SUA levels.
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